STX4 and nonpapillary renal cell carcinoma: Although we validated the pro-oncogenic effect of STX4 on ccRCC cell lines and identified STX4 as a potential biomarker to aid treatment decisions in ccRCC, several limitations to this study need to be acknowledged.